5 Biotech Stocks in Focus

Good Morning PennyStockLive, here is what I am looking at today! Advance Cell
Technology, Inc (OTC:ACTC) is a biotechnology company based in Marlborough,
Massachusetts, USA.  The company is focusing in developing stem cell based
technologies (adult and human embryonic both) and other methods and treatments
in the area of regenerative medicines. In the area of embryonic and adult stem
cell research the company has acquired, developed and maintains a portfolio of
patents and patents applications. The company is heading towards final stage
phase I clinical trials for the Retinal Pigment Epithelial (RPE) program.
StemCells, Inc. (NASDAQ:STEM) is a biotechnology company which is engaged in
discovering, developing and commercializing stem cell based technology for
academic and industrial development. In research and development the company
primarily focused on developing cellular medicine. The company has two flagship
therapeutic product development programs namely The CNS Program, which targets
in developing application for HuCNS-SC cells and human neural stem cell product
candidate, and The Liver Program, which targets in application development for
human liver engrafting cells. Recently, the company has expanded its SC proven
product portfolio with launch of proprietary human cell detection antibodies.
Aastrom Biosciences, Inc (NASDAQ: ASTM) is a pharmaceutical company which
develops enhanced cellular therapies for use in the treatment of severe, chronic
cardiovascular diseases. The Company ideology is to develop first-in-class
treatments for critical limb ischemia and dilated cardiomyopathy critical
cardiovascular diseases that currently have limited or no treatment options. The
Company has business relationship with companies like ioLife Solutions, Inc.,
Lonza Walkersville, Inc. and Invitrogen Corporation. Cell Therapeutics, Inc
(NASDAQ: CTIC) is a biopharmaceutical company which develops, acquires and
markets treatment of cancer. The Company has diversified itself into all types
of drugs related to cancer with research, development, acquisition and
in-licensing activities heavily applying on identifying and developing less
hazardous ways to treat cancer. The Company has products like pixantrone,
OPAXIO, brostallicin and bisplantinates in its product portfolio. In 2009, the
company established a JV with Spectrum pharmaceutical to develop and
commercialize Zevalin® (ibritumomab tiuxetan). Geron Corporation (NASDAQ: GERN)
is a biopharmaceutical company with headquarters in California. The Company
develops and markets drugs in the area of cancer and chronic degenerative
diseases, including spinal cord injury, heart failure and diabetes. The Company
was founded in 1990 and has around 100 employees working in the field of curing
the cancer. The Company is currently developing an anti-cancer therapy based on
telomerase inhibitors and telomerase therapeutic vaccines. The Company has a
revenue base of $3.77 million. PSL Staff This corporate profile is provided for
information purposes only and should not be used as the basis for any investment
decision. We are neither licensed nor qualified to provide investment advice. We
were not paid, nor do we hold a position in these stocks. We reserve the right
to buy or sell ACTC, STEM, ASTM, CTIC and GERN at any time after this post.